All In Biotech

Drug Trial Radar · NCT05753813

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Dec 15, 2023

Primary completion

Jan 30, 2027

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Queen's Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Hawaii Foundation
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 54 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.

Conditions

  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis

Interventions

  • PhexxiDrug

    intravaginal gel twice weekly for 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess participant's baseline vaginal microbiome makeupTime frame: Within one week of recruitment, unless menstruating. If this is the case, the participant will be asked to wait 10 days from the cessation of menses in order to allow restoration of baseline vaginal microbiome
  2. To assess if the use of Phexxi causes changes in the vaginal microbiome from baseline after thirty days of useTime frame: 30 days after baseline vaginal swab collection
  3. To assess if the use of Phexxi causes changes in the vaginal microbiomeTime frame: 60 days after baseline vaginal swab collection
  4. To assess participant's baseline vulvovaginitis symptomsTime frame: On day of recruitment to the study
  5. To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participantsTime frame: 30 days after baseline vaginal swab collection
  6. To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participantsTime frame: 60 days after baseline vaginal swab collection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queens Medical Center, 1004 Clinic POB1

    Honolulu, Hawaii · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.